Austar Lifesciences Ltd. (HK:6118)
:6118
Want to see HK:6118 full AI Analyst Report?
Top Page
Austar Lifesciences Ltd.
(6118)
Select Model
Select Model
Rating:57Neutral
Price Target:
HK$0.80
▼(-10.45% Downside)
Action:Reiterated
Date:04/30/26
The score is driven mainly by improving financials (profit recovery, better leverage, and positive recent cash generation), offset by weak technical positioning with the stock trading below key moving averages. Valuation is moderately supportive due to a reasonable P/E, but there is no dividend data to add support.
Positive Factors
Improved leverage
Deleveraging to a ~0.42 D/E from ~0.64 materially lowers financial risk and interest burden, improving solvency and funding optionality. This stronger capital structure supports investment, working-capital flexibility and resilience over the next several quarters.
Negative Factors
Thin net margins
Very low net margins constrain retained earnings and limit the company's ability to absorb cost inflation or pricing pressure. Persistently thin profitability reduces reinvestment capacity and makes growth outcomes highly sensitive to small revenue or cost swings.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved leverage
Deleveraging to a ~0.42 D/E from ~0.64 materially lowers financial risk and interest burden, improving solvency and funding optionality. This stronger capital structure supports investment, working-capital flexibility and resilience over the next several quarters.
Read all positive factors
Austar Lifesciences Ltd. (6118) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$415.19M
Dividend YieldN/A
Average Volume (3M)695.30K
Price to Earnings (P/E)11.8
Beta (1Y)0.96
Revenue Growth2.17%
EPS Growth109.41%
CountryHK
Employees1,445
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.07
Shares Outstanding512,582,030
10 Day Avg. Volume1,360,300
30 Day Avg. Volume695,300
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)0.49
Price to Sales (P/S)0.26
P/FCF Ratio4.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Austar Lifesciences Ltd. Business Overview & Revenue Model
Company Description
Austar Lifesciences Limited, an investment holding company, provides integrated engineering solutions to pharmaceutical manufacturers and research institutes in Mainland China and internationally. It operates through six segments: Liquid and Biopr...
How the Company Makes Money
null...
Austar Lifesciences Ltd. Financial Statement Overview
Summary
Income Statement
54
Neutral
Balance Sheet
66
Positive
Cash Flow
58
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.53B | 1.50B | 1.76B | 2.16B | 2.02B |
| Gross Profit | 293.27M | 301.22M | 336.05M | 488.80M | 479.01M |
| EBITDA | 73.05M | 70.71M | 25.15M | 159.79M | 130.62M |
| Net Income | 33.80M | 16.08M | -113.47M | 87.46M | 277.30M |
Balance Sheet | |||||
| Total Assets | 2.13B | 2.08B | 2.16B | 2.39B | 2.04B |
| Cash, Cash Equivalents and Short-Term Investments | 276.59M | 167.81M | 173.76M | 148.13M | 219.74M |
| Total Debt | 343.82M | 401.95M | 496.20M | 336.55M | 155.22M |
| Total Liabilities | 1.30B | 1.29B | 1.38B | 1.51B | 1.26B |
| Stockholders Equity | 822.90M | 791.41M | 773.01M | 896.94M | 786.58M |
Cash Flow | |||||
| Free Cash Flow | 99.74M | 78.31M | -133.59M | -155.25M | -204.02M |
| Operating Cash Flow | 128.24M | 98.81M | -62.65M | -37.93M | -103.45M |
| Investing Cash Flow | -15.58M | 4.43M | -54.47M | -153.14M | 65.02M |
| Financing Cash Flow | -42.76M | -101.32M | 147.12M | 125.30M | 59.35M |
Austar Lifesciences Ltd. Technical Analysis
Negative
0.89
Price Trends
0.79
Positive
0.83
Negative
0.99
Negative
Market Momentum
<0.01
Positive
49.23
Neutral
69.05
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6118, the sentiment is Negative. The current price of 0.89 is above the 20-day moving average (MA) of 0.80, above the 50-day MA of 0.79, and below the 200-day MA of 0.99, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 49.23 is Neutral, neither overbought nor oversold. The STOCH value of 69.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6118.
Austar Lifesciences Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | HK$553.90M | 5.13 | 16.21% | 4.94% | 16.46% | 50.51% | |
57 Neutral | HK$415.19M | 11.85 | 4.12% | ― | 2.17% | 109.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$160.74M | -2.82 | -17.70% | ― | -38.20% | -108.24% | |
43 Neutral | HK$523.45M | -8.27 | -11.54% | ― | -30.60% | 28.61% | |
43 Neutral | HK$617.42M | -2.30 | -21.29% | ― | -34.96% | 42.74% | |
42 Neutral | HK$423.97M | -2.05 | -17.38% | ― | -21.90% | 5.78% |
* Healthcare Sector Average
HK:6118
Austar Lifesciences Ltd.
0.80
0.11
15.94%
HK:1612
Vincent Medical Holdings Limited
0.87
0.47
117.50%
HK:2170
Suzhou Basecare Medical Corp. Ltd. Class H
1.54
-1.33
-46.34%
HK:2216
Broncus Holding Corp.
1.01
-1.16
-53.46%
HK:2393
Yestar Healthcare Holdings Co Ltd
0.07
-0.03
-28.00%
HK:2500
Venus Medtech (Hangzhou), Inc. Class H
1.35
-1.24
-47.88%
Austar Lifesciences Ltd. Corporate Events
Austar Lifesciences Sets 2026 AGM to Approve Results, Board Mandates and Share Issue Authority
Apr 23, 2026
Austar Lifesciences Limited has called its annual general meeting for 22 May 2026 in Shanghai, where shareholders will review and adopt the audited financial statements for the year ended 31 December 2025. The agenda also includes re-election of f...
Austar Lifesciences Doubles 2025 Profit on Stable Revenue and Lower Leverage
Mar 26, 2026
Austar Lifesciences Limited reported steady top-line growth for 2025, with revenue edging up to RMB1.53 billion from RMB1.50 billion a year earlier, while gross profit slipped slightly to RMB293.3 million as margin narrowed to 19.2%. Net profit mo...
Austar Lifesciences Moves to Modernise Articles Ahead of Uncertificated Regime
Mar 26, 2026
Austar Lifesciences Limited plans to overhaul its constitutional documents by adopting a second amended and restated articles of association to align with updated Hong Kong listing requirements. The revisions, which must be approved at the 22 May ...
Austar Lifesciences Sets March Board Meeting to Approve 2025 Results and Consider Final Dividend
Mar 16, 2026
Austar Lifesciences Limited has scheduled a board meeting for 26 March 2026 to review and approve the group’s annual results for the financial year ended 31 December 2025. The board will also consider whether to recommend a final dividend, a...
Austar Lifesciences Flags Near-Doubling of 2025 Profit on Cost Cuts and FX Gains
Feb 6, 2026
Austar Lifesciences Limited has issued a positive profit alert, indicating that profit attributable to shareholders for the year ended 31 December 2025 is expected to be at least RMB30 million, nearly double the approximately RMB16 million recorde...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.